Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial

The Lancet Neurology 2026

View at publisher
Authors: Matthias J Koepp, Eugen Trinka, Yee‐Haur Mah, Carla Bentes, Susanne Knake, Gian Luigi Gigli, José María Serratosa, Johan Zelano, Robert Simister, Francesco Brigo, Wolfgang Löscher, Marian Galovic
+25 more Joana Moreira, Luís M. Magalhães, Guillermo Castilla-Fernández, Helena Gama, Angelika Kippert, Valentina Di Foggia, Miguel M Fonseca, Nuno Pires, Daniel M. Ramos, Joerg Holenz, Gerhard Luef, Tim J. von Oertzen, Jörg Weber, Ummehan Ermis, Bernd Kallmünze, Holger Lerche, Carlos Martínez Quesada, Jan Rémi, Jörg B. Schulz, Yvonne Weber, Firas Fahoum, Claudia A. Granbichler, Stefan Mausbach, David Orion, Paolo Manganotti
DOI: 10.1016/s1474-4422(25)00491-0
Cited by: 5
References: 27

Fields of Study & Subjects

Epilepsy research and treatment Pharmacological Effects and Toxicity Studies Neuroscience and Neuropharmacology Research

Publication details

Journal / source
The Lancet Neurology
Publisher
Elsevier BV
Volume
25
Issue
3
Pages
256–267
Publication date
18 February 2026
Language
EN